European stocks advance as pharma giants AstraZeneca and GSK notch gains
The U.K.'s FTSE 100 led gains on Monday.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
GSK
since
auto-detected in 17 stories
68 days ago
GSK's Walmsley to step down early as insider Luke Miels named next CEO
found
GSK's CEO Emma Walmsley will step down in December and be replaced by insider Luke Miels, the British drugmaker said on Monday.
Pharma shake-up: Surprise change of CEO at GSK, as AstraZeneca announces New York stock market listing – business live
found
a story from The Guardian ⚠️ › International
Rolling coverage of the latest economic and financial news, as GSK has appointed a new boss after announcing the departure of Dame Emma Walmsley.
GSK’s Emma Walmsley to be replaced as chief executive
I…
78 days ago
ALEX BRUMMER: Donald Trump's big pharma win
found
a story from The Daily Mail 💩 › The Daily Mail
Britain's leading-edge big pharma companies AstraZeneca and GSK are pledging £59billion of investment in the US over the next five years. Spending in Blighty is on hold.
80 days ago
UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit
British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and manufacturing over the next five years.
3 months ago
Drugmaker GSK lands £372m in Covid jab pact
The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.
4 months ago
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
found
Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Regeneron, Merck, Pfizer and Novo Nordisk.
Cancer drug snub wipes £3bn off GSK value
GSK was trying to revive a product pulled from US markets in 2022. Its shares fell 4.6 per cent, or 65p, to 1348p.
7 months ago
Why your pension could be dealt a body blow as Trump eyes tariffs for Britain's top drug firms
found
a story from The Daily Mail 💩 › The Daily Mail
If the tariff-loving Trump goes ahead with his plans, it will hit AstraZeneca - the most valuable company on the UK stock market - and also rival GSK, another stalwart of the FTSE 100.
Why your pensions could be dealt a body blow as Donald Trump eyes devastating tariffs for Britain's top pharmaceutical firms - with thousands of jobs at risk: CALUM MUIRHEAD
found
a story from The Daily Mail 💩 › The Daily Mail
If the tariff-loving Trump goes ahead with his plans, it will hit AstraZeneca - the most valuable company on the UK stock market - and also rival GSK, another stalwart of the FTSE 100.